Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Net Income: 2023-2025

Historic Net Income for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to -$27.1 million.

  • Monte Rosa Therapeutics' Net Income fell 13.50% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 117.52%. This contributed to the annual value of -$72.7 million for FY2024, which is 46.27% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Net Income stood at -$27.1 million, which was down 120.26% from -$12.3 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' Net Income's 5-year high stood at $46.9 million during Q1 2025, with a 5-year trough of -$35.2 million in Q2 2023.
  • Over the past 3 years, Monte Rosa Therapeutics' median Net Income value was -$30.3 million (recorded in 2024), while the average stood at -$18.2 million.
  • Examining YoY changes over the last 5 years, Monte Rosa Therapeutics' Net Income showed a top increase of 246.58% in 2025 and a maximum decrease of 13.50% in 2025.
  • Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Net Income stood at -$33.3 million in 2023, then skyrocketed by 140.32% to $13.4 million in 2024, then dropped by 13.50% to -$27.1 million in 2025.
  • Its last three reported values are -$27.1 million in Q3 2025, -$12.3 million for Q2 2025, and $46.9 million during Q1 2025.